查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601186

藥品開發和受託製造市場：按服務、開發階段和最終用戶分類 - 2025 年至 2030 年全球預測

Pharmaceutical Contract Development & Manufacturing Market by Service, Development Stage, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年合約藥品研發受託製造市場規模為1,257.3億美元，預計2024年將達1,362.7億美元，複合年成長率為8.46%，2030年將達2,220.4億美元。

受託製造（CDMO）產業是醫療供應鏈的重要組成部分，為各種規模的製藥公司提供藥物開發、製造和包裝等基本服務。這項需求源自於製藥公司越來越需要專注於其核心競爭力，同時利用 CDMO 專業知識來簡化產品創新並更有效地將藥物推向市場。 CDMO 的範圍涵蓋整個藥物製造生命週期，包括合成、配方、臨床測試和商業生產。主要的最終用途領域包括大型製藥公司、生物技術公司和學名藥製造商。市場開拓受到生技藥品和生物相似藥需求增加、縮短藥物開發時間的壓力以及需要專業製造能力的外包增加等因素的推動。最近的機會包括擴大我們在細胞和基因治療方面的能力，利用人工智慧來最佳化流程，以及建立策略夥伴關係以增強我們的服務產品。然而，他們面臨嚴格的監管要求、高昂的初始投資成本以及影響生產計劃的供應鏈中斷等挑戰。

主要市場統計
基準年[2023] 1257.3億美元
預測年份 [2024] 1362.7億美元
預測年份 [2030] 2220.4億美元
複合年成長率（%） 8.46%

為了抓住新的資料，CDMO 專注於擴大其在個人化醫療和再生療法方面的產品，投資於連續加工和 3D 列印等尖端製造技術，並建立強大的產品組合以提高決策能力。此外，與技術提供者合作可以幫助克服該行業面臨的一些技術挑戰。先進製造基礎設施和維持遵守全球監管標準所需的高資本支出通常是有限的。 CDMO 市場本質上是動態的，其特點是技術快速進步和不斷變化的客戶需求。對研發和創新的持續投資，加上策略夥伴關係關係，使 CDMO 能夠實現持續成長，同時克服現有和新的挑戰。

市場動態：揭示快速發展的合約藥物開發和受託製造市場的關鍵市場見解

由於供需的動態相互作用，藥物開發和受託製造市場正在經歷轉型。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 對學名藥和生物治療的需求不斷成長
    • 加大醫藥研發投入
    • CDMO數量增加以及CDMO加大對先進製造技術的投資
  • 市場限制因素
    • 採用序列化
  • 市場機會
    • 對核子醫學和專科藥物的日益關注
    • 對細胞和基因治療的需求不斷增加
  • 市場問題
    • 各國的貿易政策有所不同

波特五力：駕馭藥物開發與受託製造市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解藥物開發和受託製造市場的外部影響

外部宏觀環境因素在塑造藥物開發和受託製造市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解藥物開發和受託製造市場的競爭狀況

對藥物開發和受託製造市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：藥物開發與受託製造市場中的供應商績效評估

FPNV定位矩陣是評估藥物開發和受託製造市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：規劃藥物開發和受託製造市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，藥物開發和受託製造市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對學名藥和生物療法的需求增加
      • 加大醫藥研發投入
      • CDMO數量增加以及CDMO加大對先進製造技術的投資
    • 抑制因素
      • 採用序列化
    • 機會
      • 對核子醫學和專科藥物的關注增加
      • 對細胞和基因治療的需求不斷成長
    • 任務
      • 國家間貿易政策的多樣性
  • 市場區隔分析
    • 服務：最終用戶更多採用生物製藥製造服務，以遵守嚴格的監管標準
    • 最終用戶：大型製藥公司廣泛採用製藥 CDMO 服務來管理複雜的藥物開發
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章 藥品開發與受託製造市場：依服務分類

  • 介紹
  • 生物製藥製造服務
    • 生技藥品原料藥生產服務
    • 生物製品FDF製造服務
  • 藥物開發服務
  • 藥品製造服務
    • 醫藥原料藥製造
      • 膠囊製造服務
      • 口服液製造服務
      • 注射劑/注射製造服務
      • 平板電腦製造服務
    • 製藥FDF製造
  • 二次包裝服務

第7章 藥物開發與受託製造市場：依開發階段分類

  • 介紹
  • I期臨床試驗
  • II期臨床試驗
  • III期臨床試驗
  • IV期臨床試驗
  • 臨床前

第8章 藥物開發和受託製造市場：按最終用戶分類

  • 介紹
  • 生技公司
  • 學名藥公司
  • 製藥公司
    • 大型製藥公司
    • 特種藥品
  • 中小型製藥公司

第9章 北美和南美的藥物開發和受託製造市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太藥物開發與受託製造市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的藥品開發和受託製造市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • AGC Biologics 和 BioConnection 合作提供端到端生物製藥開發和製造解決方案，以提高效率並加快上市時間
    • Kuhne Holding AG 從 BC Partners 收購 Aenova Group 多數股權，利用資源促進成長和創新
    • Alcami 宣布收購總部位於西海岸的 Pacific Pharmaceutical Services
    • Piramal Pharma 投資 100 億印度盧比擴大業務
    • eXmoor Pharma 開設 GMP 設施，成為細胞和基因治療領域的全方位服務 CDMO 合作夥伴
  • 戰略分析和建議

公司名單

  • AbbVie, Inc.
  • Acino International AG
  • Aenova Holding GmbH
  • Akums Drugs& Pharmaceuticals Ltd
  • Almac Group Limited
  • Aurobindo Pharma Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Curia Global, Inc.
  • Danaher Corporation
  • Delwis Healthcare Pvt. Ltd.
  • Evonik Industries AG
  • Fabbrica Italiana Sintetici SpA
  • Famar Health Care Services
  • FUJIFILM Diosynth BIoTechnologies USA, Inc.
  • Gerresheimer AG
  • Grifols SA
  • Hikal Ltd
  • Hovione
  • Jubilant Pharmova Limited
  • Lonza Group AG
  • Pfizer Inc.
  • Porton Pharma Solutions Ltd.
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Siegfried AG
  • The Fareva Group
  • Thermo Fisher Scientific Inc.
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • WuXi Biologics Co., Ltd.
Product Code: MRR-4316E4E8930E

The Pharmaceutical Contract Development & Manufacturing Market was valued at USD 125.73 billion in 2023, expected to reach USD 136.27 billion in 2024, and is projected to grow at a CAGR of 8.46%, to USD 222.04 billion by 2030.

The pharmaceutical contract development and manufacturing (CDMO) industry serves as a critical component in the healthcare supply chain, providing essential services such as drug development, manufacturing, and packaging to pharmaceutical companies of all sizes. Its necessity stems from the increasing need for pharmaceutical firms to focus on their core competencies while leveraging CDMO expertise to streamline product innovation and bring drugs to market more efficiently. The application scope of CDMOs spans the entire drug production lifecycle, including synthesis, formulation, clinical trials, and commercial manufacturing. Key end-use segments include large pharma companies, biotech firms, and generic drug producers. Market growth is fueled by factors such as rising demand for biologics and biosimilars, the pressure to reduce drug development time, and an increase in outsourcing activities driven by the need for specialized manufacturing capabilities. Recent opportunities include expanding capabilities in cell and gene therapies, leveraging artificial intelligence for process optimization, and forming strategic partnerships to enhance service offerings. However, the market faces challenges such as stringent regulatory requirements, high initial investment costs, and supply chain disruptions impacting production timelines.

KEY MARKET STATISTICS
Base Year [2023] USD 125.73 billion
Estimated Year [2024] USD 136.27 billion
Forecast Year [2030] USD 222.04 billion
CAGR (%) 8.46%

To capture emerging opportunities, CDMOs should focus on expanding their offerings in personalized medicine and regenerative therapies, invest in cutting-edge manufacturing technologies like continuous processing and 3D printing, and develop robust data analytics capabilities for improved decision-making. Moreover, forming alliances with technology providers can help overcome some technological challenges faced by the sector. Limitations are often related to the high capital expenditure required for advanced manufacturing infrastructure and maintaining compliance with global regulatory standards. The CDMO market is inherently dynamic, characterized by rapid technological advancements and evolving client demands, making it critical for companies to remain agile and forward-thinking. Continuous investment in R&D and innovation, paired with strategic partnerships, can position CDMOs for sustained growth while navigating existing and emerging challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmaceutical Contract Development & Manufacturing Market

The Pharmaceutical Contract Development & Manufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Demand for Generics and Biological Therapies
    • Increasing Investments in Pharmaceutical R&D
    • Increasing Number of CDMOs and Rising Investments in Advanced Manufacturing Technologies by CDMOs
  • Market Restraints
    • Introduction of Serialization
  • Market Opportunities
    • Increasing Focus on Nuclear Medicine and Specialty Drugs
    • Growing need for Cell and Gene Therapies
  • Market Challenges
    • Variable Trade Policies Between Countries

Porter's Five Forces: A Strategic Tool for Navigating the Pharmaceutical Contract Development & Manufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmaceutical Contract Development & Manufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmaceutical Contract Development & Manufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmaceutical Contract Development & Manufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmaceutical Contract Development & Manufacturing Market

A detailed market share analysis in the Pharmaceutical Contract Development & Manufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmaceutical Contract Development & Manufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmaceutical Contract Development & Manufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pharmaceutical Contract Development & Manufacturing Market

A strategic analysis of the Pharmaceutical Contract Development & Manufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pharmaceutical Contract Development & Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Acino International AG, Aenova Holding GmbH, Akums Drugs& Pharmaceuticals Ltd, Almac Group Limited, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Curia Global, Inc., Danaher Corporation, Delwis Healthcare Pvt. Ltd., Evonik Industries AG, Fabbrica Italiana Sintetici S.p.A., Famar Health Care Services, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Gerresheimer AG, Grifols S.A., Hikal Ltd, Hovione, Jubilant Pharmova Limited, Lonza Group AG, Pfizer Inc., Porton Pharma Solutions Ltd., Recipharm AB, Samsung Biologics Co., Ltd., Siegfried AG, The Fareva Group, Thermo Fisher Scientific Inc., Vetter Pharma-Fertigung GmbH & Co. KG, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Pharmaceutical Contract Development & Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Service, market is studied across Biologics Manufacturing Services, Drug Development Services, Pharmaceutical Manufacturing Services, and Secondary Packaging Services. The Biologics Manufacturing Services is further studied across Biologics API Manufacturing Services and Biologics FDF Manufacturing Services. The Pharmaceutical Manufacturing Services is further studied across Pharmaceutical API Manufacturing and Pharmaceutical FDF Manufacturing. The Pharmaceutical API Manufacturing is further studied across Capsule Manufacturing Services, Oral Liquid Manufacturing Services, Parenteral/Injectable Manufacturing Services, and Tablet Manufacturing Services.
  • Based on Development Stage, market is studied across Phase I Clinical Trials, Phase II Clinical Trials, Phase III Clinical Trials, Phase IV Clinical Trials, and Preclinical.
  • Based on End User, market is studied across Biotechnology Companies, Generic Pharmaceutical Companies, Pharmaceutical Companies, and Small & Mid-Size Pharma. The Pharmaceutical Companies is further studied across Big Pharma and Specialty Pharma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Demand for Generics and Biological Therapies
      • 5.1.1.2. Increasing Investments in Pharmaceutical R&D
      • 5.1.1.3. Increasing Number of CDMOs and Rising Investments in Advanced Manufacturing Technologies by CDMOs
    • 5.1.2. Restraints
      • 5.1.2.1. Introduction of Serialization
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing Focus on Nuclear Medicine and Specialty Drugs
      • 5.1.3.2. Growing need for Cell and Gene Therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Variable Trade Policies Between Countries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Service: Rising penetration of biologics manufacturing services by end-users to adhere to stringent regulatory standards
    • 5.2.2. End User: Big pharma companies widely adopting pharmaceutical CDMO services to manage complex drug development
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pharmaceutical Contract Development & Manufacturing Market, by Service

  • 6.1. Introduction
  • 6.2. Biologics Manufacturing Services
    • 6.2.1. Biologics API Manufacturing Services
    • 6.2.2. Biologics FDF Manufacturing Services
  • 6.3. Drug Development Services
  • 6.4. Pharmaceutical Manufacturing Services
    • 6.4.1. Pharmaceutical API Manufacturing
      • 6.4.1.1. Capsule Manufacturing Services
      • 6.4.1.2. Oral Liquid Manufacturing Services
      • 6.4.1.3. Parenteral/Injectable Manufacturing Services
      • 6.4.1.4. Tablet Manufacturing Services
    • 6.4.2. Pharmaceutical FDF Manufacturing
  • 6.5. Secondary Packaging Services

7. Pharmaceutical Contract Development & Manufacturing Market, by Development Stage

  • 7.1. Introduction
  • 7.2. Phase I Clinical Trials
  • 7.3. Phase II Clinical Trials
  • 7.4. Phase III Clinical Trials
  • 7.5. Phase IV Clinical Trials
  • 7.6. Preclinical

8. Pharmaceutical Contract Development & Manufacturing Market, by End User

  • 8.1. Introduction
  • 8.2. Biotechnology Companies
  • 8.3. Generic Pharmaceutical Companies
  • 8.4. Pharmaceutical Companies
    • 8.4.1. Big Pharma
    • 8.4.2. Specialty Pharma
  • 8.5. Small & Mid-Size Pharma

9. Americas Pharmaceutical Contract Development & Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Pharmaceutical Contract Development & Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Pharmaceutical Contract Development & Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. AGC Biologics and BioConnection join forces to provide end-to-end biopharmaceutical development and manufacturing solutions, enhancing efficiency and speeding up market delivery.
    • 12.3.2. Kuhne Holding AG acquires majority stake in Aenova Group from BC Partners, leveraging resources for enhanced growth and innovation
    • 12.3.3. Alcami Announces Acquisition of West-Coast-Based Pacific Pharmaceutical Services
    • 12.3.4. Piramal Pharma to Invest INR 1,000 Crore for Expansion
    • 12.3.5. eXmoor Pharma Expands into Full-Service Cell and Gene Therapy CDMO Partner with Opening of GMP Facilities
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Acino International AG
  • 3. Aenova Holding GmbH
  • 4. Akums Drugs& Pharmaceuticals Ltd
  • 5. Almac Group Limited
  • 6. Aurobindo Pharma Limited
  • 7. Boehringer Ingelheim International GmbH
  • 8. Cambrex Corporation
  • 9. Catalent, Inc.
  • 10. Curia Global, Inc.
  • 11. Danaher Corporation
  • 12. Delwis Healthcare Pvt. Ltd.
  • 13. Evonik Industries AG
  • 14. Fabbrica Italiana Sintetici S.p.A.
  • 15. Famar Health Care Services
  • 16. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • 17. Gerresheimer AG
  • 18. Grifols S.A.
  • 19. Hikal Ltd
  • 20. Hovione
  • 21. Jubilant Pharmova Limited
  • 22. Lonza Group AG
  • 23. Pfizer Inc.
  • 24. Porton Pharma Solutions Ltd.
  • 25. Recipharm AB
  • 26. Samsung Biologics Co., Ltd.
  • 27. Siegfried AG
  • 28. The Fareva Group
  • 29. Thermo Fisher Scientific Inc.
  • 30. Vetter Pharma-Fertigung GmbH & Co. KG
  • 31. WuXi Biologics Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS API MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS FDF MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DRUG DEVELOPMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY CAPSULE MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY ORAL LIQUID MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PARENTERAL/INJECTABLE MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY TABLET MANUFACTURING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL FDF MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SECONDARY PACKAGING SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE I CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE II CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHASE IV CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIG PHARMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SPECIALTY PHARMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SMALL & MID-SIZE PHARMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY SERVICE, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY BIOLOGICS MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL MANUFACTURING SERVICES, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA PHARMACEUTICAL CONTRACT DEVELOPMENT & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL API MANUFACTURING, 2018-2030 (USD MILLION)
  • TABLE 241.